ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2017
Hepatic DsbA-L protects mice from diet-induced hepatosteatosis and insulin resistance.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- DsbA-L safeguards T cell mitochondrial redox homeostasis to restrain Th17 differentiation and colitis.Cell death & disease · 2026Article
- The SIRT3-DsbA-L-TFAM axis restrains cGAS-driven metabolic dysfunction-associated steatohepatitis in male mice.Nature communications · 2026Article
- The role of Western diet and gut microbiota in the pathogenesis of cardiovascular diseases.Frontiers in microbiology · 2026Review
- GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control.Journal of experimental & clinical cancer research : CR · 2025Article
- DsbA-L: A Promising Therapeutic Target for Metabolic Diseases.Current medicinal chemistry · 2025Review
- New insights of DsbA-L in the pathogenesis of metabolic diseases.Molecular and cellular biochemistry · 2024Review
- DsbA-L ameliorates renal aging and renal fibrosis by maintaining mitochondrial homeostasis.Acta pharmacologica Sinica · 2024Article
- DsbA-L interacting with catalase in peroxisome improves tubular oxidative damage in diabetic nephropathy.Redox biology · 2023Article
- Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration.Diabetes · 2021Article
- DsbA-L deficiency in T cells promotes diet-induced thermogenesis through suppressing IFN-γ production.Nature communications · 2021Article
- DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice.Nature communications · 2020Article
- Mitochondrial stress protein HSP60 regulates ER stress-induced hepatic lipogenesis.Journal of molecular endocrinology · 2020Article
- Resveratrol reduces liver endoplasmic reticulum stress and improves insulin sensitivity in vivo and in vitro.Drug design, development and therapy · 2019Article
- Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.CPT: pharmacometrics & systems pharmacology · 2018Article
- Cytosolic sensing of immuno-stimulatory DNA, the enemy within.Current opinion in immunology · 2018Review
- DsbA-L prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-activated cGAS-cGAMP-STING pathway.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver.International journal of molecular sciences · 2017Review
- Silencing of DsbA-L gene impairs the PPARγ agonist function of improving insulin resistance in a high-glucose cell model.Journal of Zhejiang University. Science. BArticle
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
Abstract
Hepatic insulin resistance and hepatosteatosis in diet-induced obesity are associated with various metabolic diseases, yet the underlying mechanisms remain to be fully elucidated. Here we show that the expression levels of the disulfide-bond A oxidoreductase-like protein (DsbA-L) are significantly reduced in the liver of obese mice and humans. Liver-specific knockout or adenovirus-mediated overexpression of DsbA-L exacerbates or alleviates, respectively, high-fat diet-induced mitochondrial dysfunction, hepatosteatosis, and insulin resistance in mice. Mechanistically, we found that DsbA-L is localized in mitochondria and that its deficiency is associated with impairment of maximum respiratory capacity, elevated cellular oxidative stress, and increased JNK activity. Our results identify DsbA-L as a critical regulator of mitochondrial function, and its down-regulation in the liver may contribute to obesity-induced hepatosteatosis and whole body insulin resistance.-Chen, H., Bai, J., Dong, F., Fang, H., Zhang, Y., Meng, W., Liu, B., Luo, Y., Liu, M., Bai, Y., Abdul-Ghani, M. A., Li, R., Wu, J., Zeng, R., Zhou, Z., Dong, L. Q., Liu, F. Hepatic DsbA-L protects mice from diet-induced hepatosteatosis and insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.